US EditionPublished • loading... • Updated
In Gaillac, Pierre Fabre Strengthens French Health Sovereignty by Relocating Two Strategic Anticancer Drugs Under a €30 Million Envelope
Summary by usinenouvelle.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The visit of Sébastien Martin, Minister Delegate for Industry, to the Pierre Fabre laboratory site in Gaillac, on Friday 16 January, was fully part of the French strategy for the relocation of critical pharmaceutical productions. The Occitan group has put in service new manufacturing lines dedicated to two strategic anticancer active principles: encorafenib and binimetinib marketed under the names Braftovi and Mektovi. An industrial project supp…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
